QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.117580v1 321/1/389    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Totah, R. A. Articles by Kharasch, E. D. Search for Related Content PubMed PubMed Citation Articles by Totah, R. A. Articles by Kharasch, E. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METHADONE RIFAMPIN

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism

Department of Medicinal Chemistry (R.A.T., K.E.A.) and Department of Anesthesiology (P.S., D.W.), University of Washington. Seattle, Washington; and Division of Clinical and Translational Research, Department of Anesthesiology, Washington University, St. Louis, Missouri (E.D.K.)

Methadone is administered as a racemate, although opioid activity resides in the R-enantiomer. Methadone disposition is stereoselective, with considerable unexplained variability in clearance and plasma R/S ratios. N-Demethylation of methadone in vitro is predominantly mediated by cytochrome P450 CYP3A4 and CYP2B6 and somewhat by CYP2C19. This investigation evaluated stereoselectivity, models, and kinetic parameters for methadone N-demethylation by recombinant CYP2B6, CYP3A4, and CYP2C19, and the potential for interactions between enantiomers during racemate metabolism. CYP2B6 metabolism was stereoselective. CYP2C19 was less active, and stereoselectivity was opposite that for CYP2B6. CYP3A4 was not stereoselective. With all three isoforms, enantiomer N-dealkylation rates in the racemate were lower than those of (R)-(6-dimethyamino-4,4-diphenyl-heptan-3-one) hydrochloride (R-methadone) or (S)-(6-dimethyamino-4,4-diphenyl-heptan-3-one) hydrochloride (S-methadone) alone, suggesting an enantiomeric interaction and mutual metabolic inhibition. For CYP2B6, the interaction between enantiomers was stereoselective, with S-methadone as a more potent inhibitor of R-methadone N-demethylation than R-of S-methadone. In contrast, enantiomer interactions were not stereoselective with CYP2C19 or CYP3A4. For all three cytochromes P450, methadone N-demethylation was best described by two-site enzyme models with competitive inhibition. There were minor model differences between cytochromes P450 to account for stereoselectivity of metabolism and enantiomeric interactions. Changes in plasma R/S methadone ratios observed after rifampin or troleandomycin pretreatment in humans in vivo were successfully predicted by CYP2B6- but not CYP3A4-catalyzed methadone N-demethylation. CYP2B6 is a predominant catalyst of stereoselective methadone metabolism in vitro. In vivo, CYP2B6 may be a major determinant of methadone metabolism and disposition, and CYP2B6 activity and stereoselective metabolic interactions may confer variability in methadone disposition.

Address correspondence to: Dr. Evan Kharasch, Department of Anesthesiology, Washington University, 660 S. Euclid Ave., Campus Box 8054, St. Louis, MO 63110-1093. E-mail: kharasch{at}wustl.edu

This article has been cited by other articles:

				S. W. Smith Chiral Toxicology: It's the Same Thing...Only Different Toxicol. Sci., July 1, 2009; 110(1): 4 - 30. [Abstract] [Full Text] [PDF]

				H. S. Smith Opioid Metabolism Mayo Clin. Proc., July 1, 2009; 84(7): 613 - 624. [Abstract] [Full Text] [PDF]

				S. De Fazio, L. Gallelli, A. De Siena, G. De Sarro, and M. G. Scordo Role of CYP3A5 in Abnormal Clearance of Methadone Ann. Pharmacother., June 1, 2008; 42(6): 893 - 897. [Abstract] [Full Text] [PDF]

				E. D. Kharasch, D. Mitchell, R. Coles, and R. Blanco Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1663 - 1669. [Abstract] [Full Text] [PDF]

				E. D. Kharasch, D. Mitchell, and R. Coles Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity J. Clin. Pharmacol., April 1, 2008; 48(4): 464 - 474. [Abstract] [Full Text] [PDF]

				M. Scholler-Gyure, W. van den Brink, T. N. Kakuda, B. Woodfall, G. De Smedt, H. Vanaken, T. Stevens, M. Peeters, K. Vandermeulen, and R. M. W. Hoetelmans Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV-Negative Volunteers J. Clin. Pharmacol., March 1, 2008; 48(3): 322 - 329. [Abstract] [Full Text] [PDF]